Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sinovac Approved to Launch 23-Valent Pneumonia Vaccine in China

publication date: Dec 9, 2020

Sinovac Biotech, a Beijing vaccine company, reported China regulators approved its 23-Valent Pneumococcal Polysaccharide (PPV) Vaccine to prevent streptococcus pneumonia in adults and children ages 2 years old and above. Sinovac began work on the vaccine in 2009 and initiated clinical trials in 2014. A Phase III study showed it was the equal of other vaccines in all 23 pneumonia serotypes. The product is Sinovac's first vaccine for a bacterial target. More details....

Stock Symbols: (NSDQ: SVA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.